智通财经网·2026-03-30 15:25Core Insights - The company reported a revenue of 14.095 billion yuan for the year 2025, representing a year-on-year growth of 14.82% [1] - The net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan, while the net profit excluding non-recurring items increased by 38.85% to 1.538 billion yuan [1] - The basic earnings per share were 0.9443 yuan, and the company proposed a cash dividend of 2 yuan per 10 shares (tax included) [1] Business Strategy - The company emphasizes a customer-centric service philosophy and leverages an integrated service platform to meet diverse global client needs across different research and development stages [1] - Significant achievements were noted in expanding strategic client relationships, particularly with large pharmaceutical companies [1] - The company is actively enhancing its market strategies tailored to the Chinese market, resulting in rapid growth in client business within China [1] Market Performance - The company achieved a more than 14% year-on-year increase in new order amounts for 2025 [1] - The company maintains industry leadership in small molecule fields while also experiencing rapid development in new molecular type projects [1]